Clinical TrialMay 19, 2026, 07:06 AM
Tiziana Reports Positive Clinical Data for Foralumab in na-SPMS
AI Summary
Tiziana Life Sciences announced new positive clinical data from its ongoing Expanded Access Program for intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The updated data, covering March 2025 to March 2026, showed that foralumab was extremely well tolerated over extended treatment durations. Patients exhibited encouraging trends in disability stabilization as measured by EDSS and meaningful improvements in fatigue, with 64% achieving a clinically significant improvement in MFIS scores. While the small sample size means the data is not statistically significant, it supports further investigation into foralumab as a potential treatment.
Key Highlights
- Updated clinical data from ongoing Expanded Access (EA) Program for intranasal foralumab in na-SPMS.
- Evaluated intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
- Data updated from March 2025 to March 2026, showing continued excellent tolerability.
- Patients showed encouraging trends in stabilization of disability (EDSS).
- 64% of patients achieved a clinically meaningful improvement of ">=4 points" in their MFIS score.
- Data is not statistically significant due to small sample size, representing a trend analysis only.
Price Impact
More from TLSA